8-K current report · filed Nov 12, 2026

Intellia Therapeutics, Inc. (NTLA) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1NTLA overview

Short answer

Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Investor presentation focused on preparing lonvo-z for patients with hereditary angioedema.

Intellia Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Investor presentation focused on preparing lonvo-z for patients with hereditary angioedema
  • Event provides an update on commercial readiness and potential launch execution for lonvo-z
  • Exhibit 99.1 contains the detailed presentation materials for investors

Item EX-99.1 · Exhibit EX-99.1

  • Lonvo-z BLA accepted with FDA priority review, PDUFA decision target March 10, 2027, accelerating potential commercial launch
  • Phase 3 HAELO met primary and key secondary endpoints, reducing attack rate 62% versus 11% with placebo
  • Attack-free weeks increased 87%, with odds ratio 12.8 and p<0.0001, supporting a potentially differentiated one-time treatment
  • Lonvo-z 50 mg showed durable effects through 4 years, with 100% of patients LTP-free at latest cutoff
  • Commercial readiness work is underway, but approval and launch remain contingent on FDA review and manufacturing execution

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Intellia Therapeutics, Inc. 8-K filings

Get the next NTLA 8-K as it lands

Follow NTLA for push alerts, or ask the research agent what this filing means.